Consensus Legend Biotech Corporation

Equities

LEGN

US52490G1022

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-29 EDT			5-day change	1st Jan Change
45.14 ^USD	-0.35%		-4.08%	-24.98%

04-23	Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission	MT
04-22	Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer	MT

Evolution of the average Target Price on Legend Biotech Corporation

Price target over the last 5 years

History of analyst recommendation changes

ba8896b789ff7466a063f07652.GfQN_o6hSMatX0qHKG5A_mG3CRCDtAF_hI0oY6RDQno.a6xvq_31CvPuOj_saQ92qgfoZGH3hjg76MgYOpEaBgpxxniN_Zcs8sUWcg~871ce5dd0deccde15df6903316ed1e68

Analyst Recommendations on Legend Biotech Corporation

Scotiabank Upgrades Legend Biotech to Sector Outperform From Sector Perform, Price Target is $65	04-17	MT
Cantor Fitzgerald Initiates Legend Biotech With Overweight Rating	04-03	MT
UBS Adjusts Legend Biotech Price Target to $81 From $76, Maintains Buy Rating	03-18	MT
Raymond James Starts Legend Biotech With Outperform Rating, $86 Price Target	03-13	MT
RBC Trims Price Target on Legend Biotech to $85 From $86, Keeps Outperform Rating	01-03	MT
Scotiabank Initiates Legend Biotech With Sector Perform Rating, $65 Price Target	12-19	MT
Earnings, Interest Rates Cap Wall Street Pre-Bell; Asia Choppy, Europe Up	11-20	MT
HC Wainwright Raises Price Target on Legend Biotech to $87 From $86, Keeps Buy Rating	11-15	MT
HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $85, Keeps Buy Rating	23-10-18	MT
Barclays Adjusts Price Target on Legend Biotech to $93 From $92, Maintains Overweight Rating	23-10-18	MT
Barclays Adjusts Price Target on Legend Biotech to $92 From $90, Maintains Overweight Rating	23-07-21	MT
HC Wainwright Adjusts Price Target on Legend Biotech to $85 From $82, Maintains Buy Rating	23-07-21	MT
Morgan Stanley Raises Price Target on Legend Biotech to $85 From $65, Maintains Overweight Rating	23-07-20	MT
BTIG Raises Price Target on Legend Biotech to $90 From $85, Maintains Buy Rating	23-06-13	MT
HC Wainwright Adjusts Legend Biotech Price Target to $82 From $77, Maintains Buy Rating	23-06-06	MT
William Blair Initiates Legend Biotech at Market Perform	23-05-25	MT
Daiwa Securities Initiates Legend Biotech at Buy Rating	23-05-22	MT
Barclays Adjusts Price Target on Legend Biotech to $90 From $65, Keeps Overweight Rating	23-05-19	MT
RBC Boosts Price Target on Legend Biotech to $83 From $74, Cites Greater Confidence in Manufacturing Progress, Keeps Outperform Rating	23-05-19	MT
BMO Capital Adjusts Price Target on Legend Biotech to $90 From $79, Maintains Outperform Rating	23-04-25	MT
HC Wainwright Adjusts Price Target on Legend Biotech to $77 From $66, Maintains Buy Rating	23-04-20	MT
BTIG Adjusts Price Target on Legend Biotech to $85 From $75, Maintains Buy Rating	23-04-20	MT
JPMorgan Adjusts Price Target on Legend Biotech to $76 From $65, Maintains Overweight Rating	23-04-19	MT
RBC Capital Lifts Legend Biotech Price Target to $74 From $73, Maintains Outperform Rating	23-04-06	MT
UBS Adjusts Legend Biotech's Price Target to $76 From $66, Maintains Buy Rating	23-01-30	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

45.14 USD

Average target price

86.33 USD

Spread / Average Target

+91.25%

High Price Target

95 USD

Spread / Highest target

+110.46%

Low Price Target

65 USD

Spread / Lowest Target

+44.00%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Legend Biotech Corporation

Scotiabank
Cantor Fitzgerald
UBS
Raymond James
RBC Capital Markets
HC Wainwright
Barclays
Morgan Stanley
BTIG
William Blair & Co.
Daiwa Securities
BMO Capital
JPMorgan Chase
Piper Sandler
Cowen
Guggenheim

Ratings for Legend Biotech Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar